Summit Therapeutics: PDUFA Coming, But Is It Good Enough? (Rating Upgrade) [Seeking Alpha]
Summit Therapeutics Inc. (SMMT)
Last summit therapeutics inc. earnings: 6/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
summitplc.com/investors/investor-centre
Company Research
Source: Seeking Alpha
SMMT's lead asset, ivonescimab, faces an FDA decision for EGFR-mutant NSCLC by November 2026, with PFS benefit but uncertain overall survival impact. Liquidity is solid with $710 million in cash and 2-2.5 years of runway, but substantial milestone and royalty obligations to Akesobio remain. While SMMT's commercial prospects hinge on FDA approval, Akesobio's mature pipeline and ongoing trials provide additional near-term catalysts. Frazao Studio Latino/E+ via Getty Images Topline Summary and Update I've had notable issues with Summit Therapeutics' ( SMMT ) rise to prominence over the past couple of years, taking measured excitement from their first-ever show of force against the immunotherapy This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am no
Show less
Read more
Impact Snapshot
Event Time:
SMMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SMMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SMMT alerts
High impacting Summit Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
SMMT
News
- Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.MarketBeat
- Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Summit Therapeutics (NASDAQ:SMMT) had its "market outperform" rating reaffirmed by analysts at Citizens Jmp. They now have a $40.00 price target on the stock.MarketBeat
- Summit Therapeutics (NASDAQ:SMMT) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
SMMT
Earnings
- 10/20/25 - Beat
SMMT
Sec Filings
- 1/29/26 - Form 8-K
- 1/12/26 - Form 4
- 1/12/26 - Form 8-K
- SMMT's page on the SEC website